The use of advanced therapies, including biologics and small molecules, has become an established clinical practice for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). However, certain patient populations, such as those with a history of cancer, are often excluded from clinical trials evaluating the efficacy and safety of these therapies. This exclusion has historically left clinicians with limited evidence to guide treatment decisions in this high-risk group. Nevertheless, emerging real-world data and updated guidelines increasingly support the safe use of advanced therapies in patients with a prior malignancy. Risk stratification and a multidisciplinary approach, including oncologist input, remain critical in optimizing patient outcomes by assessing both cancer recurrence risk and disease activity. This review aims to provide a comprehensive overview of the current evidence, address existing knowledge gaps, and offer practical insights for the management of IBD in patients with a history of cancer.
生物制剂和小分子药物等先进疗法已成为治疗中重度溃疡性结肠炎和克罗恩病的成熟临床手段。然而，在评估这些疗法有效性与安全性的临床试验中，癌症病史患者等特定人群常被排除在外。这一传统做法导致临床医生在指导此类高风险群体治疗决策时长期缺乏循证依据。值得关注的是，新兴的真实世界数据与更新指南日益支持既往恶性肿瘤患者安全使用先进疗法。通过综合评估癌症复发风险与疾病活动度，结合肿瘤专科医师意见进行风险分层及多学科协作，对优化患者预后至关重要。本综述旨在系统梳理现有证据，探讨当前认知空白，并为癌症病史患者的炎症性肠病管理提供实践指导。
肿瘤(癌症)患者之家